Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice

Hironobu Takano, Toru Nakamura, Takahiro Tsuchikawa, Toshihiro Kushibiki, Kouji Hontani, Kazuho Inoko, Mizuna Takahashi, Shoki Sato, Hirotake Abe, Shintaro Takeuchi, Nagato Sato, Kei Hiraoka, Hiroshi Nishihara, Toshiaki Shichinohe, Satoshi Hirano

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Ephrin receptor A4 (EphA4) is overexpressed in human pancreatic adenocarcinoma (PDAC) and activate cell growth. Recent studies have identified small molecules that block EphA4. In this study, we investigated the correlation between EphA4 expression and the prognosis of patients with PDAC. We also examined the cytostatic efficacy of 2,5-dimethylpyrrolyl benzoic acid (compound 1), a small molecule that blocks EphA4, in PDAC cells. Overall survival of patients with EphA4 positivity was significantly shorter than that of patients with EphA4 negativity (P = 0.029). In addition, multivariate analysis revealed that EphA4 expression was an independent prognostic factor in PDAC patients (P = 0.039). Compound 1 showed a cytostatic efficacy in PDAC cells expressing EphA4 in vitro and in vivo. Our study indicated that compound 1 suppressed both EphA4 and Akt phosphorylations, and induced apoptosis in PDAC cells expressing EphA4. In conclusion,compound 1 has a high potential as a therapeutic agent for patients with PDAC.

Original languageEnglish
Pages (from-to)41063-41076
Number of pages14
JournalOncotarget
Volume6
Issue number38
DOIs
Publication statusPublished - 2015 Jan 1
Externally publishedYes

Fingerprint

EphA4 Receptor
EphA1 Receptor
Benzoic Acid
Pancreatic Neoplasms
Nude Mice
Cytostatic Agents
Proxy

Keywords

  • 2,5-dimethylpyrrolyl benzoic acid
  • EphA4
  • Human pancreatic cancer
  • Orthotopic models
  • Prognostic factor

ASJC Scopus subject areas

  • Oncology

Cite this

Takano, H., Nakamura, T., Tsuchikawa, T., Kushibiki, T., Hontani, K., Inoko, K., ... Hirano, S. (2015). Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. Oncotarget, 6(38), 41063-41076. https://doi.org/10.18632/oncotarget.5729

Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. / Takano, Hironobu; Nakamura, Toru; Tsuchikawa, Takahiro; Kushibiki, Toshihiro; Hontani, Kouji; Inoko, Kazuho; Takahashi, Mizuna; Sato, Shoki; Abe, Hirotake; Takeuchi, Shintaro; Sato, Nagato; Hiraoka, Kei; Nishihara, Hiroshi; Shichinohe, Toshiaki; Hirano, Satoshi.

In: Oncotarget, Vol. 6, No. 38, 01.01.2015, p. 41063-41076.

Research output: Contribution to journalArticle

Takano, H, Nakamura, T, Tsuchikawa, T, Kushibiki, T, Hontani, K, Inoko, K, Takahashi, M, Sato, S, Abe, H, Takeuchi, S, Sato, N, Hiraoka, K, Nishihara, H, Shichinohe, T & Hirano, S 2015, 'Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice', Oncotarget, vol. 6, no. 38, pp. 41063-41076. https://doi.org/10.18632/oncotarget.5729
Takano, Hironobu ; Nakamura, Toru ; Tsuchikawa, Takahiro ; Kushibiki, Toshihiro ; Hontani, Kouji ; Inoko, Kazuho ; Takahashi, Mizuna ; Sato, Shoki ; Abe, Hirotake ; Takeuchi, Shintaro ; Sato, Nagato ; Hiraoka, Kei ; Nishihara, Hiroshi ; Shichinohe, Toshiaki ; Hirano, Satoshi. / Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. In: Oncotarget. 2015 ; Vol. 6, No. 38. pp. 41063-41076.
@article{945b34a5963c442d9dc2d172bd0e3bb4,
title = "Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice",
abstract = "Ephrin receptor A4 (EphA4) is overexpressed in human pancreatic adenocarcinoma (PDAC) and activate cell growth. Recent studies have identified small molecules that block EphA4. In this study, we investigated the correlation between EphA4 expression and the prognosis of patients with PDAC. We also examined the cytostatic efficacy of 2,5-dimethylpyrrolyl benzoic acid (compound 1), a small molecule that blocks EphA4, in PDAC cells. Overall survival of patients with EphA4 positivity was significantly shorter than that of patients with EphA4 negativity (P = 0.029). In addition, multivariate analysis revealed that EphA4 expression was an independent prognostic factor in PDAC patients (P = 0.039). Compound 1 showed a cytostatic efficacy in PDAC cells expressing EphA4 in vitro and in vivo. Our study indicated that compound 1 suppressed both EphA4 and Akt phosphorylations, and induced apoptosis in PDAC cells expressing EphA4. In conclusion,compound 1 has a high potential as a therapeutic agent for patients with PDAC.",
keywords = "2,5-dimethylpyrrolyl benzoic acid, EphA4, Human pancreatic cancer, Orthotopic models, Prognostic factor",
author = "Hironobu Takano and Toru Nakamura and Takahiro Tsuchikawa and Toshihiro Kushibiki and Kouji Hontani and Kazuho Inoko and Mizuna Takahashi and Shoki Sato and Hirotake Abe and Shintaro Takeuchi and Nagato Sato and Kei Hiraoka and Hiroshi Nishihara and Toshiaki Shichinohe and Satoshi Hirano",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.5729",
language = "English",
volume = "6",
pages = "41063--41076",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "38",

}

TY - JOUR

T1 - Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice

AU - Takano, Hironobu

AU - Nakamura, Toru

AU - Tsuchikawa, Takahiro

AU - Kushibiki, Toshihiro

AU - Hontani, Kouji

AU - Inoko, Kazuho

AU - Takahashi, Mizuna

AU - Sato, Shoki

AU - Abe, Hirotake

AU - Takeuchi, Shintaro

AU - Sato, Nagato

AU - Hiraoka, Kei

AU - Nishihara, Hiroshi

AU - Shichinohe, Toshiaki

AU - Hirano, Satoshi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Ephrin receptor A4 (EphA4) is overexpressed in human pancreatic adenocarcinoma (PDAC) and activate cell growth. Recent studies have identified small molecules that block EphA4. In this study, we investigated the correlation between EphA4 expression and the prognosis of patients with PDAC. We also examined the cytostatic efficacy of 2,5-dimethylpyrrolyl benzoic acid (compound 1), a small molecule that blocks EphA4, in PDAC cells. Overall survival of patients with EphA4 positivity was significantly shorter than that of patients with EphA4 negativity (P = 0.029). In addition, multivariate analysis revealed that EphA4 expression was an independent prognostic factor in PDAC patients (P = 0.039). Compound 1 showed a cytostatic efficacy in PDAC cells expressing EphA4 in vitro and in vivo. Our study indicated that compound 1 suppressed both EphA4 and Akt phosphorylations, and induced apoptosis in PDAC cells expressing EphA4. In conclusion,compound 1 has a high potential as a therapeutic agent for patients with PDAC.

AB - Ephrin receptor A4 (EphA4) is overexpressed in human pancreatic adenocarcinoma (PDAC) and activate cell growth. Recent studies have identified small molecules that block EphA4. In this study, we investigated the correlation between EphA4 expression and the prognosis of patients with PDAC. We also examined the cytostatic efficacy of 2,5-dimethylpyrrolyl benzoic acid (compound 1), a small molecule that blocks EphA4, in PDAC cells. Overall survival of patients with EphA4 positivity was significantly shorter than that of patients with EphA4 negativity (P = 0.029). In addition, multivariate analysis revealed that EphA4 expression was an independent prognostic factor in PDAC patients (P = 0.039). Compound 1 showed a cytostatic efficacy in PDAC cells expressing EphA4 in vitro and in vivo. Our study indicated that compound 1 suppressed both EphA4 and Akt phosphorylations, and induced apoptosis in PDAC cells expressing EphA4. In conclusion,compound 1 has a high potential as a therapeutic agent for patients with PDAC.

KW - 2,5-dimethylpyrrolyl benzoic acid

KW - EphA4

KW - Human pancreatic cancer

KW - Orthotopic models

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=84951174360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951174360&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5729

DO - 10.18632/oncotarget.5729

M3 - Article

VL - 6

SP - 41063

EP - 41076

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 38

ER -